---
id: 168
title: Blastomyces dermatitidis (Blastomycosis)
category: organisms
subcategory: endemic_fungi
tags: [Blastomyces, blastomycosis, Great-Lakes, itraconazole, amphotericin, broad-based-budding]
difficulty: medium
---

## Question

What are the key features and treatment of blastomycosis? Use the **"Endemic (Great Lakes), Pulmonary + Skin (Verrucous Lesions), Broad-Based Budding → Itraconazole (Mild) or AmB (Severe)"** framework.

## Answer

### ***Blastomyces dermatitidis* Overview:**

**Geography:**
- **Endemic:** Great Lakes, Ohio/Mississippi River Valleys, Southeastern US, Canadian provinces
- **Soil exposure** (moist soil near waterways, decaying organic matter)

**Transmission:** Inhalation of conidia (airborne spores)

### **Clinical Syndromes:**

**Pulmonary Blastomycosis (Most Common Presentation):**

**Presentation:**
- **Subacute to chronic** pneumonia (weeks to months)
- **Fever, cough, chest pain, weight loss, night sweats** (mimics TB, malignancy)
- **Can be acute** (flu-like, self-limited) or chronic/progressive

**CXR:**
- **Consolidation** (lobar or patchy, upper lobes common)
- **Mass lesions** (can mimic malignancy)
- **Cavitation** (less common than histoplasmosis)
- **Pleural effusion** (10-20%)

**Outcome:**
- **Can be self-limited** in some immunocompetent, but **treatment usually recommended** (risk of dissemination)

**Cutaneous Blastomycosis (40-80% of Disseminated Cases):**

**Presentation:**
- **Verrucous (warty) lesions:** Raised, crusted, violaceous borders
- **Ulcerative lesions:** Central ulceration with raised borders
- **Slowly progressive** (enlarging over weeks to months)
- **Can mimic:** Squamous cell carcinoma, pyoderma gangrenosum

**Sites:** Face, extremities (exposed areas)

**Pathophysiology:** Hematogenous dissemination from pulmonary source (or direct inoculation, rare)

**Osteoarticular Blastomycosis (10-30%):**

**Presentation:**
- **Osteomyelitis:** Long bones, vertebrae (back pain, paravertebral abscess)
- **Septic arthritis:** Knee, ankle, wrist

**Imaging:**
- **Lytic bone lesions** (can mimic malignancy)

**CNS Blastomycosis (5-10%):**

**Presentation:**
- **Brain abscess:** Focal neurologic deficits, seizures, headache
- **Meningitis:** Fever, headache, altered mental status

**Imaging:**
- **Ring-enhancing lesions** (mimic toxoplasmosis, bacterial abscess)

**Outcome:**
- **High mortality** without treatment

**Genitourinary Blastomycosis:**
- **Prostatitis, epididymo-orchitis** (men)

### **Diagnosis:**

**Histopathology (Gold Standard for Rapid Diagnosis):**
- **Broad-based budding yeast** (8-15 μm, thick-walled)
- **Single bud** attached by broad base (distinguishes from *Cryptococcus* narrow-based budding)
- **GMS or PAS stain**

**Culture:**
- **Gold standard for species confirmation** (slow, 1-4 weeks)
- **Sputum, BAL, skin biopsy, tissue**

**Antigen Detection:**
- **Urine *Blastomyces* antigen** (cross-reacts with *Histoplasma*)
- **Sensitivity 90%** (disseminated), lower (isolated pulmonary)
- **Monitor treatment response** (levels decline)

**Serology:**
- **NOT recommended** (poor sensitivity, cross-reactivity)

### **Treatment:**

**Mild-Moderate Pulmonary / Cutaneous:**
- **Itraconazole 200mg PO TID × 3 days, then 200mg PO BID × 6-12 months**

**Severe Pulmonary / CNS / Disseminated:**
- **Liposomal amphotericin B 3-5 mg/kg IV daily × 1-2 weeks** (until clinically improved)
- **Then:** **Itraconazole 200mg PO TID × 3 days, then 200mg PO BID × 12 months**

**CNS:**
- **Liposomal amphotericin B 5 mg/kg IV daily × 4-6 weeks**
- **Then:** **Itraconazole 200mg PO BID-TID × ≥12 months** (consider voriconazole or posaconazole for better CSF penetration)

**Osteoarticular:**
- **Itraconazole 200mg PO BID × 12 months** (mild-moderate)
- **AmB initially if severe** → switch to itraconazole

**Pregnancy:**
- **Liposomal amphotericin B** (azoles contraindicated in pregnancy)

**Itraconazole Monitoring:**
- **Check levels** (trough 1-2 mcg/mL)
- **Drug interactions** (CYP3A4 inhibitor)

## Key Points

### **Broad-Based Budding:**
- **Hallmark:** Large yeast (8-15 μm) with single bud attached by **broad base**
- **Distinguishes from *Cryptococcus*** (narrow-based budding)

### **Verrucous Skin Lesions:**
- **Raised, crusted, violaceous borders**
- **Mimics malignancy** (squamous cell carcinoma)
- **Biopsy essential** (rule out cancer)

### **Treat All Cases:**
- **Unlike histoplasmosis** (which is often self-limited), **blastomycosis usually treated**
- **Risk of dissemination** even in immunocompetent

### **CNS = High Mortality:**
- **Brain abscess** (ring-enhancing)
- **High-dose AmB × 4-6 weeks** → itraconazole × ≥12 months
- **Consider voriconazole/posaconazole** (better CSF penetration than itraconazole)

### **Urine Antigen:**
- **Sensitivity 90%** in disseminated disease
- **Cross-reacts with *Histoplasma*** (may need follow-up testing)
- **Monitor treatment response** (levels decline)

### **Endemic Geography:**
- **Great Lakes region** (Wisconsin, Minnesota, Michigan, Ontario)
- **Ohio/Mississippi River Valleys, Southeastern US**
- **Soil near waterways** (moist soil, decaying organic matter)

### **Clinical Pearls:**
- **Endemic:** Great Lakes region (soil near waterways)
- **Pulmonary + verrucous skin lesions** (mimics malignancy)
- **Broad-based budding yeast** (8-15 μm, thick-walled)
- **Treat all cases:** Itraconazole × 6-12 months (mild) OR AmB → itraconazole (severe)
- **CNS:** High mortality, AmB × 4-6 weeks → itraconazole ≥12 months
- **Urine antigen 90% sensitive** (disseminated), cross-reacts with *Histoplasma*

## Sources

- [IDSA: Blastomycosis Guidelines 2024]
- [CID: Blastomycosis Review 2024]

## Media

N/A
